Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Published May 10, 2026Diabetes, obesity & metabolism

How Oral Semaglutide Levels Relate Differently to Blood Sugar Control, Weight Loss, and Digestive Side Effects

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Page updated May 11, 2026

Abstract

In a cohort of 256 patients, HbA1c levels declined by 0.7% and body weight by 7.5% over a median follow-up of 19 months.

Estimated individual exposure (eC) to oral semaglutide is associated with changes in body weight and gastrointestinal side effects.
Both prescribed dose and eC were significantly linked to improvements in HbA1c and body weight when analyzed separately.
The prescribed dose outperformed eC in predicting glycaemic response, while eC showed a better fit for weight loss outcomes.
The relationship between exposure and weight loss was notably different from that of glycaemic effects.
eC remained a significant predictor of gastrointestinal side effects after accounting for the prescribed dose.

AI simplified

AIMS: Oral semaglutide absorption is subject to inter-individual variability. We investigated whether estimated individual exposure (eC) provides predictive information beyond the prescribed dose in a real-world cohort of patients with type 2 diabetes (T2D). avg

MATERIALS AND METHODS: We retrospectively included patients initiating oral semaglutide to calculate eCat each follow-up visit, using a validated population pharmacokinetic model incorporating dose, weight, sex, ethnicity and GI disorders, but without measuring plasma semaglutide concentrations. Mixed-effects models were used to assess the associations of dose and eCwith changes in HbA1c and percent body weight, and to compare model fit. For GI side effects, time-adjusted fixed-effects logistic regression was employed. avg avg

RESULTS: We analysed 256 participants (31.6% women, mean age 65.6 years). During a median follow-up of 19 months, HbA1c declined by 0.7% and body weight by 7.5%; 41.8% of patients reported GI side effects. Both dose and eCwere significantly associated with all outcomes when analysed individually. For ΔHbA1c, the dose model outperformed the eCmodel (p < 0.01), while eCshowed modestly improved fit for weight loss (p < 0.001). The exposure-effect relationship was clearly right-shifted for weight loss compared to the glycaemic effect. For GI side effects, eCremained significantly associated with the outcome after adjustment for dose residuals, indicating that eChad greater predictive value for tolerability. avg avg avg avg avg

CONCLUSIONS: Although estimated and not measured, the exposure to oral semaglutide may provide outcome-dependent information. While the prescribed dose seems sufficient to predict glycaemic response, estimated exposure provides additional value for weight loss and GI tolerability.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief